Arcturus Therapeutics Ltd (NASDAQ:ARCT) has been given a consensus rating of “Hold” by the eight brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $3.45.

ARCT has been the topic of several recent analyst reports. Ladenburg Thalmann Financial Services initiated coverage on shares of Arcturus Therapeutics in a research report on Wednesday, November 29th. They set a “buy” rating on the stock. Chardan Capital initiated coverage on shares of Arcturus Therapeutics in a research report on Monday, January 22nd. They set a “buy” rating and a $12.00 price objective on the stock.

Arcturus Therapeutics (NASDAQ:ARCT) opened at $5.93 on Friday. Arcturus Therapeutics has a 1-year low of $5.78 and a 1-year high of $15.19. The firm has a market cap of $73.45, a P/E ratio of -1.48 and a beta of 1.44.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.07). analysts predict that Arcturus Therapeutics will post -1.31 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was originally published by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2018/02/08/arcturus-therapeutics-ltd-arct-given-average-recommendation-of-hold-by-analysts.html.

About Arcturus Therapeutics

Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms.

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.